Takeda Officially Opens Development Center in China

Reinforces Takeda’s Strategic Commitment to Asia and to China

Takeda Global Research and Development Asia, Pte. Ltd. (“TGRD (Asia)”) and Takeda Shanghai Development Center (“TSDC”) announced on August 8th the official opening of TSDC. TSDC is based within the Shanghai-based Takeda (China) Holdings Co., Ltd. (“TCH”), which is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (Osaka, Japan). This follows the announcement earlier this year by Takeda on the establishment of TSDC which reinforces Takeda’s strategic commitment to Asia and to China in particular.

The opening announcement was made in conjunction with a clinical development symposium organised by TSDC and China Center for Pharmaceutical International Exchange (CCPIE). This symposium brought together Asian regulatory officials, medical key opinion leaders (KOLs), China and world leading pharmaceutical R&D leaders and other clinical development peers to discuss R&D development strategies to address China unmet medical needs.

Dr Benny Li, Head of TSDC, said, “The establishment of TSDC provides a powerful addition to Takeda’s global development infrastructure. The opening of TSDC will extend and enhance the company’s clinical development activities within Asia with a focus on China for General Medicine and across Asia (outside Japan) for Oncology. Through the addition of TSDC’s capabilities, Takeda will continue to conduct high quality clinical trials which will lead to securing regulatory approvals in Asia.” China is the third largest pharmaceutical market in the world(1) and it is also said to be an especially strong oncology market(2).

With the addition of the TSDC, Takeda has enhanced its business in China through TCH’s wholly owned subsidiaries, Takeda Pharmaceutical (China) Company Limited in Taizhou (“Takeda China”) which is responsible for marketing and sales, and Tianjin Takeda Pharmaceuticals Co., Ltd, in Tianjin (“Tianjin Takeda”) which is responsible for manufacturing. Together with Takeda China and Tianjin Takeda, TSDC will help to drive Takeda’s ambitious growth agenda in China and in the broader Asian region.

Within Asia, excluding Japan, drug development is overseen by TGRD Asia in Singapore and in oncology by Millennium: The Takeda Oncology Company in Cambridge, Massachusetts, wholly owned subsidiaries of Takeda.

(1) http://www.imshealth.com/ims/Global/Content/Insights/Featured%20Topics/Launch%20Excellence/Harberingers.pdf

(2) http://www.imshealth.com/ims/Global/Content/Insights/Featured%20Topics/Emerging%20Markets/APAC_Oncology.pdf

About Takeda Shanghai Development Center

Based in Shanghai, China, Takeda Shanghai Development Center (TSDC) resides within the Shanghai-based Takeda (China) Holdings Co., Ltd., which is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. TSDC conducts Takeda’s clinical development activities within the Asian region, with a focus on China for non-oncology working as an integrated regional team with Takeda Global Research and Development Center Asia, and across Asia for oncology with Millennium: The Takeda Oncology Company. To learn more about these Takeda companies, visit www.takeda.com .

About Takeda Global Research and Development Center Asia, Pte. Ltd.

Headquartered in Singapore, Takeda Global Research and Development Center Asia, Pte. Ltd. (TGRD Asia) is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. Fully integrated into the global development organisation, TGRD Asia serves as a regional hub for non-oncology clinical development. TGRD Asia seeks to bring innovative products to patients through a pipeline that includes compounds in development for metabolic and cardiovascular diseases, respiratory and immunology, central nervous system diseases and other therapeutic areas. For more information on Takeda, visit www.takeda.com .

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com .

SOURCE Takeda

• ข่าวTakeda Global Research
• ข่าวo:prncn
• ข่าวo:heal
• ข่าวo:gen
• ข่าวo:prn